Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

American Journal of Cardiology

Volumn 88, Issue 3, 2001, Pages 270-274

  McKenney, James M ^a,d   McCormick, Lisa S ^b   Schaefer, Ernst J ^c   Black, Donald M ^b   Watkins, Michael L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d National Clinical Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; ISOPROTEIN; LIPOPROTEIN; NICOTINIC ACID; SMALL LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FEMALE; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; NIACIN; PYRROLES;

EID: 0035423283     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01639-3     Document Type: Article

References (30)

1. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
2. Does measurement of apolipoprotein B have a place in cholesterol management?
3. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in man. Prospective results from the Quebec Cardiovascular Study
4. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
5. Lipoprotein subclasses in the Monitored Athosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiography progression
6. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients
7. Reduction of LDL-cholesterol by 25% to 60% in patients with hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
8. Efficacy and safety of a new HMG-CoA reductase inhibitor in patients with hypertriglyceridemia
9. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglcerdemia
10. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement
11. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
12. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia
13. A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction
14. Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women
15. Athrogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
16. Low-density lipoprotein subclass patterns and risk of myocardial infarction
17. Effect of nicotinic acid on LDL subclass patterns
18. Effects of fluvastatin (XU-62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans
19. Effects of pravastatin treatment on lipoportein subclass profiles and particle size in the PLAC-1 trial
20. Atorvastatin substantially reduces small dense LDL subpopulation in patients with coronary heart disease
21. Identification of multiple subclasses of plasma low density lipoproteins in normal humans
22. Hypertriglyceridemia as a cardiovascular risk factor
23. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment
24. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
25. Management of primary hyperlipidemia
26. Management of dyslipidemia in NIDDM
27. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglycerdemic patients
28. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease
29. Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations
30. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women